Ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1) mRNA (UBE2V1 mRNA)

Ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1) mRNA encodes a protein that is a key regulator of non-canonical Lys-63-linked polyubiquitination. While the protein itself lacks catalytic activity, it forms a heterodimer with UBE2N (Ubc13) to facilitate the assembly of ubiquitin chains that mediate signal transduction rather than proteasomal degradation (UniProt Q13404). This process is vital for the activation of the NF-kappaB pathway and the DNA damage bypass mechanism known as post-replication repair (NCBI Gene ID: 7335). UBE2V1 mRNA is frequently upregulated in various cancers, including breast, colon, and prostate cancer, where it contributes to epithelial-mesenchymal transition (EMT), metastasis, and chemoresistance (PubMed: 25639193, 22493330). Therapeutic targeting of UBE2V1 mRNA via RNA interference (RNAi) or antisense oligonucleotides (ASOs) aims to reduce the cellular pool of UBE2V1 protein, thereby inhibiting oncogenic signaling and sensitizing tumor cells to treatment. Although small molecule inhibitors like NSC697923 target the protein complex, mRNA-directed therapies offer a highly specific approach to modulating this pathway in inflammatory and neoplastic diseases.

Other names

CROC1 mRNAUEV1 mRNAUEV1A mRNACIR1 mRNAUbiquitin-conjugating enzyme E2 variant 1 transcript

RNA interference or antisense-mediated degradation of the UBE2V1 transcript to prevent translation of the UBE2V1 protein.